Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7263732 | 0.76 | GRIN2D (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL892215 | 0.75 | GRIN2D (0.30) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1071740 | 0.74 | GRIN2D (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6291331 | 0.74 | NPSR1 (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL677091 | 0.74 | HSD11B1 (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3873892 | 0.69 | — | — | |
| SCHEMBL3179851 | 0.68 | KMT2A (0.35) | — | |
| SCHEMBL23631362 | 0.67 | ALDH1A1 (0.38) | — | |
| SCHEMBL6830167 | 0.67 | — | — | |
| SCHEMBL2220414 | 0.66 | THRB (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807070-A1 | COMBINATIONS OF SUBSTITUTED AZETIDINONES AND CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006039334-A1 | COMBINATIONS OF SUBSTITUTED AZETIDONONES AND CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069080-A1 | Combinations of substituted azetidinones and CB1 antagonists | SCHERING CORPORATION | 2006-03-30 | — | — | US | disclosed |
| US-5624941-A | Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-04-29 | — | — | US | disclosed |
| EP-0576357-B1 | Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1997-03-05 | — | — | EP | disclosed |
| EP-0576357-A1 | Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1993-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069080-A1 | Combinations of substituted azetidinones and CB1 antagonists | CNR1, CNR2, GPR119 | GRIN2D 1572/4885GRIN3B 990/4885GRIN1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.